CenterBook Partners LP Sells 15,272 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

CenterBook Partners LP lowered its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 78.6% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,162 shares of the company’s stock after selling 15,272 shares during the period. CenterBook Partners LP’s holdings in Kiniksa Pharmaceuticals International were worth $311,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $1,161,000. OMERS ADMINISTRATION Corp purchased a new position in Kiniksa Pharmaceuticals International during the first quarter valued at $631,000. Handelsbanken Fonder AB purchased a new position in Kiniksa Pharmaceuticals International during the second quarter valued at $1,343,000. The Manufacturers Life Insurance Company boosted its holdings in Kiniksa Pharmaceuticals International by 56.7% in the first quarter. The Manufacturers Life Insurance Company now owns 63,346 shares of the company’s stock worth $3,050,000 after acquiring an additional 22,917 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Kiniksa Pharmaceuticals International by 213.5% in the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock worth $23,197,000 after acquiring an additional 327,595 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Michael R. Megna sold 36,260 shares of the business’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $94.43, for a total transaction of $3,424,031.80. Following the completion of the sale, the chief accounting officer owned 12,697 shares of the company’s stock, valued at $1,198,977.71. The trade was a 74.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 77,587 shares of the company’s stock in a transaction on Friday, October 30th. The stock was sold at an average price of $93.02, for a total value of $7,217,142.74. Following the completion of the sale, the insider owned 69,922 shares of the company’s stock, valued at $6,504,144.44. This trade represents a 52.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 842,302 shares of company stock valued at $78,587,130. 51.98% of the stock is currently owned by corporate insiders.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $96.33 on Friday. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $99.31. The company has a market cap of $7.57 billion, a P/E ratio of 74.10 and a beta of 0.07. The stock’s fifty day moving average price is $82.18 and its 200-day moving average price is $62.70.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. As a group, analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on KNSA. Citigroup upped their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Canaccord Genuity Group lifted their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 28th. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Finally, Wells Fargo & Company upped their price target on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and a consensus price target of $100.57.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.